Related Experiment Video
Updated: Aug 2, 2026
10:13
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
NXY-059: review of neuroprotective potential for acute stroke
Jeffrey J Fong1, Denise H Rhoney
1Tufts-New England Medical Center, Northeastern University School of Pharmacy, Boston, MA, USA.
The Annals of Pharmacotherapy
|March 2, 2006
Summary
NXY-059, a novel neuroprotective agent, shows promise in treating acute stroke by reducing infarct volume and disability. Early trials indicate good tolerability, with potential to advance stroke care.
Area of Science:
- Neuroscience
- Pharmacology
- Emergency Medicine
Background:
- Acute stroke remains a leading cause of disability worldwide.
- Current treatment options for acute stroke are limited, highlighting the need for novel therapeutic agents.
- NXY-059 is an investigational nitrone-based free radical trapping agent developed for acute stroke treatment.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, efficacy, and tolerability of NXY-059.
- To evaluate the potential role of NXY-059 in the management of acute stroke.
Main Methods:
- Comprehensive literature search of MEDLINE (1966-February 2006) using keywords: NXY-059, cerovive, nitrones, neuroprotection, free radical trapper, and secondary neurologic injury.
- Evaluation of data from animal and human trials, including published and unpublished studies and abstracts.
- Analysis of Phase II and Phase III clinical trial data.
Main Results:
- NXY-059 demonstrated reductions in infarct volume and neurologic deficits in animal models.
- Pharmacokinetic studies showed a predictable profile with primary renal elimination.
- Phase II trials indicated favorable safety and tolerability.
- A Phase III trial analysis revealed a statistically significant reduction in disability in patients treated with NXY-059 compared to placebo.
Conclusions:
- NXY-059 is a novel agent progressing through Phase III trials for acute stroke.
- Initial data suggest a favorable safety profile, with no serious adverse events noted, except for potential accumulation in renal insufficiency.
- NXY-059 has the potential to significantly alter acute stroke management and improve patient care.
